References
Product Reference: |●Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation: J.H. Hanke, et al.; J. Biol. Chem. 271, 695 (1996)|●Src family-selective tyrosine kinase inhibitor, PP1, inhibits both Fc epsilonRI- and Thy-1-mediated activation of rat basophilic leukemia cells: M. Amoui, et al.; Eur. J. Immunol. 27, 1881 (1997) |●Lck associates with and is activated by Kit in a small cell lung cancer cell line: inhibition of SCF-mediated growth by the Src family kinase inhibitor PP1: G.W. Krystal, et al.; Cancer Res. 58, 4660 (1998)|●An anti-Ras cancer potential of PP1, an inhibitor specific for Src family kinases: in vitro and in vivo studies: H. He, et al.; Cancer J. 6, 243 (2000)|●The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes: F. Carlomagno, et al.; Cancer Res. 62, 1077 (2002)|●The specificities of protein kinase inhibitors: an update: J. Bain, et al.; Biochem. J. 371, 199 (2003)|●The Src-selective kinase inhibitor PP1 also inhibits Kit and Bcr-Abl tyrosine kinases: L. Tatton, et al.; J. Biol. Chem. 278, 4847 (2003)|●Src activation is not necessary for transforming growth factor (TGF)-beta-mediated epithelial to mesenchymal transitions (EMT) in mammary epithelial cells. PP1 directly inhibits TGF-beta receptors I and II: M. Maeda, et al.; J. Biol. Chem. 281, 59 (2006)|●The selectivity of protein kinase inhibitors: a further update: J. Bain, et al.; Biochem. J. 408, 297 (2007)|●The Src family kinase inhibitors PP2 and PP1 block TGF-beta1-mediated cellular responses by direct and differential inhibition of type I and type II TGF-beta receptors: H. Ungefroren, et al.; Curr. Cancer Drug Targets 11, 524 (2011)|●USBio References
No references available
TDS
NCBI
UniProt
Tech Support
Customer Service
